Editorials

Charting a path through resistance: HDAC inhibitors for TP53-mutated B-acute lymphoblastic leukemia

Department of Leukemia, UT MD Anderson Cancer Center, Houston TX, USA Rabin Medical Center and Faculty of Medicine, Aviv University, Aviv
Haematologica Early view Feb 15, 2024 https://doi.org/10.3324/haematol.2023.284796